# Auto Review: results.txt

Generated: 2026-04-28 20:31
Reviewer: Qwen2.5-32B-Instruct-AWQ (auto_review.py)

## Summary

- **Samples**: 30
- **Clean**: 0/30
- **P0** (hallucination): 0
- **P1** (major error): 29
- **P2** (minor issue): 136

### Critical Issues

- **ROW 4** [P1]: Incomplete sentence, missing information about other medications like DexAMETHasone and ondansetron.
- **ROW 6** [P1]: The note mentions 'lanreotide', not 'capecitabine'.
- **ROW 6** [P1]: The date mentioned is from 2015, which is not recent and does not align with the context of a follow-up visit.
- **ROW 7** [P1]: Inaccurate staging information. The correct stage is pT3 N1, not Stage II-III.
- **ROW 14** [P1]: Inaccurate description of the tumor location. The tumor is of duodenal/ampullary origin, not pancreatic.
- **ROW 15** [P1]: The sentence is too long and complex for an 8th-grade reading level.
- **ROW 15** [P1]: The sentence is incomplete and lacks clarity on the specific medication.
- **ROW 18** [P1]: Inaccurate description of the cancer growth. The note mentions 'new and enlarging hypermetabolic pulmonary metastases', which is more specific and detailed than 'grown slightly'.
- **ROW 21** [P1]: Incomplete information about the medication. The dose details are missing.
- **ROW 29** [P1]: Inaccurate statement; the patient is a new patient with a new diagnosis.
- **ROW 31** [P1]: Missing cancer-related medication (gemcitabine).
- **ROW 31** [P1]: This sentence contains medical jargon that may be difficult for an 8th-grade reader to understand.
- **ROW 32** [P1]: Incomplete sentence with missing critical information (name of the medication).
- **ROW 33** [P1]: Inaccurate description of the cancer status. The note indicates 'interval increase in size of primary infiltrative necrotic pancreatic head mass' and 'similar in size and appearance of multiple hepatic metastases'. The letter incorrectly states that the cancer in the liver remains stable, which is misleading.
- **ROW 35** [P1]: Use of 'hepatic lesions' is jargon that should be simplified to 'liver'.
- **ROW 35** [P1]: Incomplete sentence, missing the specific types of medications.
- **ROW 35** [P1]: Unexplained jargon 'hereditary pancreatic cancer syndrome'.
- **ROW 36** [P1]: Inaccurate description of the imaging findings. The original note states that some lesions have increased in size while others have decreased, but it does not specify 'shrunk'.
- **ROW 40** [P1]: Incomplete sentence with missing critical information (dose amount).
- **ROW 43** [P1]: Incomplete sentence with missing critical information.
- **ROW 72** [P1]: Missing current cancer-related medication (gemcitabine and Abraxane).
- **ROW 77** [P1]: The sentence is incomplete and lacks clarity about the surgical procedure.
- **ROW 79** [P1]: The term 'pancreaticobiliary' is not explained and may be confusing to an 8th-grade reader.
- **ROW 82** [P1]: Incomplete sentence with missing critical info (missing 'FOLFOXIRI').
- **ROW 90** [P1]: The note mentions both primary pancreatic neuroendocrine tumor and metastatic BRAF mutant melanoma, but the extracted data only lists 'Primary pancreatic neuroendocrine tumor'.
- **ROW 90** [P1]: The note indicates the patient is on intermittent dabrafenib and trametinib for melanoma, but this is not reflected in the extracted data.
- **ROW 90** [P1]: Incomplete sentence with missing critical information.
- **ROW 91** [P1]: Inaccurate description of the pathology results. It should mention 'residual adenocarcinoma' rather than just 'remaining cancer'.
- **ROW 92** [P1]: Incomplete sentence with missing critical info.

---

## ROW 1 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic adenocarcinoma
**Stage**: Potentially resectable with a regional LN involvement

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (palonosetron). | He initiated ***** on 03/06/2022, once his LFTs had sufficiently normalized post-stent, and is now s |
| P2 | Lab_Results | Missing initial CA 19-9 value (77,736). | Baseline *****-9 markedly elevated at 77,736 (in the context of obstructive jaundice) |
| P2 | Treatment_Changes | Missing mention of palonosetron. | He initiated ***** on 03/06/2022, once his LFTs had sufficiently normalized post-stent, and is now s |
| P2 | Treatment_Goals | Inaccurate goal description. Should include 'potentially curative' rather than just 'curative'. | We reviewed his most recent imaging studies which show, quite encouragingly, resolution of his aorto |
| P2 | Response_Assessment | Missing mention of the drop in CA 19-9 from 77,736 to 6,105. | Baseline *****-9 markedly elevated at 77,736 (in the context of obstructive jaundice) |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing specific cancer-related medications and lab results.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 4 — ⚠️ ISSUES

**Type**: Metastatic pancreatic ductal adenocarcinoma
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine-based regimen mentioned as a potential future treatment, but not listed under current medications). | We talked about potential side fx and risks, esp in terms of infectious complications, and adverse i |
| P2 | Treatment_Changes | Supportive medications listed include general pain medications (Fentanyl patch, Dilaudid) without specifying they are for cancer pain. | Symptom-wise, he is followed by our Cancer Center Symptom Management Service; his pain appears reaso |
| P2 | Treatment_Goals | Goals of treatment are listed as 'palliative', but the patient is still considering further salvage treatment options. | Mr. ***** will take some time to decide whether he wishes to pursue further salvage rx vs a purely p |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing potential future cancer treatments, unclear classification of supportive medications, and slight misrepresentation of treatment goals.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence, missing information about other medications like DexAMETHasone and ondansetron. | You are currently on a combination of long- and short-acting opioid analgesics f |

*Letter summary*: Letter has one minor completeness issue.

---

## ROW 6 — ⚠️ ISSUES

**Type**: Well-differentiated neuroendocrine tumor, grade 1, with lymphovascular and perin
**Stage**: Originally Stage IIB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | The note mentions 'lanreotide', not 'capecitabine'. | continue lanreotide 120 mg/mo |
| P2 | Cancer_Diagnosis | The note does not specify the original stage as 'IIB'. | Primary pancreatic neuroendocrine tumor s/p [REDACTED] procedure in 2013. |

*Extraction summary*: Major error in current medications and minor issue in cancer diagnosis stage. Other fields are clean.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The date mentioned is from 2015, which is not recent and does not align with the context of a follow-up visit. | Imaging from October 5, 2015, shows that the cancer in your liver and lymph node |
| P2 | Capecitabine is listed under 'Current Medications', but the treatment plan mentions continuing lanreotide. Capecitabine is not part of the current treatment plan. | You continue to take capecitabine. |

*Letter summary*: The letter contains issues with outdated information and incorrect medication details.

---

## ROW 7 — ⚠️ ISSUES

**Type**: Well-differentiated pancreatic ductal adenocarcinoma
**Stage**: pT3 N1

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. The note mentions metformin, methylphenidate, ondansetron, and oxycodone, but only ondansetron and oxycodone are listed under supportive_meds. However, only cancer-related medications should be included in current_meds. | Medications the patient states to be taking prior to today's encounter. METFORMIN HCL (METFORMIN ORA |
| P2 | Treatment_Changes | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Treatment_Goals | Inaccurate. The goal is adjuvant therapy, not curative. The note mentions that the patient is receiving adjuvant chemotherapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Response_Assessment | Inaccurate. The response assessment should include the patient's current condition and the absence of disease recurrence, not just the improvement in labs. | The patient's labs are noted to be significantly improved, allowing continuation of gemcitabine. The |
| P2 | Medication_Plan | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Therapy_plan | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |

*Extraction summary*: Most fields are clean, but there are minor issues with completeness and accuracy in medication and treatment plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate staging information. The correct stage is pT3 N1, not Stage II-III. | You have a well-differentiated pancreatic ductal adenocarcinoma (cancer that sta |
| P2 | Unnecessary detail about the date of the CT scan. | Recent CT scan on 10/21/2015 shows post-operative changes without evidence of re |
| P2 | Unexplained jargon 'labs'. | Your labs are noted to be significantly improved, allowing continuation of gemci |
| P2 | Incomplete sentence with missing critical info. | Beginning cycle #4, the a medication-paclitaxel was discontinued due to cumulati |

*Letter summary*: The letter contains inaccuracies and minor readability issues.

---

## ROW 14 — ⚠️ ISSUES

**Type**: Grade 3 neuroendocrine tumor of duodenal/ampullary origin
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Missing temozolomide. | She is now s/p 5 cycles of chemotherapy consisting of the combination of capecitabine/temozolomide. |
| P2 | Treatment_Changes | Incomplete. Missing dose adjustments of capecitabine due to renal insufficiency. | Because of progressive renal insufficiency early on during her treatment course, I dose reduced her  |

*Extraction summary*: Most fields are clean, but there are minor omissions regarding current medications and treatment changes.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate description of the tumor location. The tumor is of duodenal/ampullary origin, not pancreatic. | You came in for a follow-up visit regarding your neuroendocrine tumor of the pan |
| P2 | Minor readability issue. Could be clearer. | MRI scans from early June showed that your disease is stable. |
| P2 | Minor readability issue. Could be more specific. | During your physical exam, no new issues were found. |
| P2 | Minor readability issue. Could specify side effects. | You will continue to take ondansetron and oxycodone to manage side effects. |
| P2 | Minor readability issue. Could be more specific. | After this cycle, you will have a CT scan to check on your tumor. |

*Letter summary*: The letter contains inaccuracies and minor readability issues.

---

## ROW 15 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Originally Stage IV, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note does not explicitly state the original stage of the cancer, only that it is metastatic adenocarcinoma of the pancreas. The extraction infers 'Originally Stage IV, now metastatic (Stage IV)', which is slightly imprecise. | This is a very pleasant 35-year-old Hispanic male who was diagnosed in October 2015 with metastatic  |
| P2 | Treatment_Changes.recent_changes | The note mentions that the patient will resume an unspecified agent, but the exact nature of the previous treatment is not clear. The extraction states 'He responded initially quite well to [REDACTED]', which is slightly imprecise without specifying the treatment. | We will resume [REDACTED]. He responded initially quite well to [REDACTED] but because of his residu |
| P2 | Imaging_Plan.imaging_plan | The note mentions a recent CT scan, but it does not specify future imaging plans. The extraction states 'CT Chest', which is slightly imprecise without further context. | Report dictated by: ***** ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology  |

*Extraction summary*: Most fields are clean, but there are minor issues with the inferred stage, unspecified treatment, and future imaging plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The sentence is too long and complex for an 8th-grade reading level. | There has been a progression of extensive peritoneal disease. You have developed |
| P1 | The sentence is incomplete and lacks clarity on the specific medication. | We will resume a medication. You initially responded well to a medication, but d |
| P2 | Unexplained jargon 'CT Chest scan'. | A CT Chest scan is planned for monitoring. |

*Letter summary*: The letter contains issues with readability and clarity, particularly around medical terminology and sentence structure.

---

## ROW 17 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine and capecitabine). | She has now had 4 full cycles and returns today for follow-up imaging. When we last saw her, she had |
| P2 | Treatment_Changes | Missing ongoing chemotherapy (gemcitabine and capecitabine). | She will continue on chemotherapy without dose or schedule modification and we will also start denos |
| P2 | Imaging_Plan | Inaccurate imaging plan, should include both CT Chest and CT Abdomen/Pelvis. | She will continue on chemotherapy without dose or schedule modification and we will also start denos |

*Extraction summary*: Most fields are clean, but there are minor issues regarding missing ongoing chemotherapy and an inaccurate imaging plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | The term 'cancer spot' is somewhat vague and could be clearer. | The CT scan of your abdomen and pelvis shows that a small cancer spot in your li |
| P2 | While 'tumor marker' is acceptable, it might be clearer to specify that CA 19-9 is a blood test. | Your CA 19-9, a tumor marker, has gone down from 13,468 to 4,187. |

*Letter summary*: Letter is mostly clean with minor readability issues.

---

## ROW 18 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma, 2.1 cm, invading duodenal submucosa, negative 
**Stage**: pT2N0

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | Medication Instructions:  amLODIPine (NORVASC) 5 mg, Oral, Every Morning Before Breakfast Scheduled |
| P2 | Treatment_Changes | Supportive medications listed are not fully supported by the note. | Some cumulative treatment-related peripheral sensory neuropathy, decreased appetite and dysgeusia. S |
| P2 | Lab_Results | Inaccurate representation of lab results. | Recent lab results show elevated CA 19-9 levels, with the most recent value being 1,077 U/mL on 11/1 |
| P2 | Treatment_Goals | Goals of treatment should be 'palliative' but are not explicitly stated. | We discussed the implications of these findings and how they should inform the next steps and timing |
| P2 | Radiotherapy_plan | Incomplete description of radiotherapy plan. | I will refer him to our Rad Onc team here at ***** for this possibility. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications, incomplete supportive medication listing, inaccurate lab results, unclear treatment goals, and incomplete radiotherapy plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate description of the cancer growth. The note mentions 'new and enlarging hypermetabolic pulmonary metastases', which is more specific and detailed than 'grown slightly'. | Recent imaging shows that the cancer in your lungs has grown slightly. |
| P2 | The note specifies the exact values of CA 19-9, which provides more context. The letter should reflect this detail. | Your CA 19-9 (a tumor marker) level has also increased. |
| P2 | The note mentions 'modest dose reductions along the way' and 'building in a treatment hiatus'. The letter should clarify the reason for the break. | You will take a break from treatment to let your body recover from side effects. |

*Letter summary*: The letter contains inaccuracies and lacks some important details that should be included for clarity.

---

## ROW 21 — ⚠️ ISSUES

**Type**: Metastatic pancreatic cancer
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (irinotecan). | On this basis, he initiated 2nd-line chemotherapy consisting of the combination of 5-*****/LV plus * |
| P2 | Treatment_Changes | Missing detail about dose reduction of irinotecan. | Due to obstipation and anorexia following cycle #1, his doses were reduced by 20% beginning with cyc |
| P2 | Therapy_plan | Incorrectly states 'Continue/start: irinotecan'. The patient is no longer a candidate for further treatment. | Therefore we had a ***** goals of care discussion in which I recommended that he refocus his goals p |

*Extraction summary*: Most fields are clean, but there are minor issues regarding the inclusion of cancer-related medications and the therapy plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete information about the medication. The dose details are missing. | You are now taking loperamide to manage diarrhea. |

*Letter summary*: Letter has minor issues with incomplete medication information.

---

## ROW 29 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | Inaccurate summary; mentions 'new diagnosis' instead of 'follow-up'. | This is an independent visit. |
| P2 | Current_Medications.current_meds | Incomplete; only lists Gemcitabine and Abraxane, but does not include other cancer-related medications like Zoledronic acid. | She elected to go on the ***** 301 trial. |
| P2 | Treatment_Changes.recent_changes | Incomplete; only lists Gemcitabine and Abraxane, but does not include other cancer-related medications like Zoledronic acid. | She elected to go on the ***** 301 trial. |
| P2 | Treatment_Changes.supportive_meds | Incomplete; includes only some supportive medications, missing others like Ritalin and Mirtazapine. | Continue Ritalin BID. Followed by SMS. Continue on Mirtazapine 115mg qHS. Followed by SMS. |
| P2 | Medication_Plan.medication_plan | Incomplete; does not include Ritalin and Mirtazapine. | Continue Ritalin BID. Followed by SMS. Continue on Mirtazapine 15mg qHS. Followed by SMS. |
| P2 | Therapy_plan.therapy_plan | Incomplete; does not include Ritalin and Mirtazapine. | Continue Ritalin BID. Followed by SMS. Continue on Mirtazapine 15mg qHS. Followed by SMS. |

*Extraction summary*: Most fields are clean, but there are minor issues with the summary, current medications, and supportive medications lists.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate statement; the patient is a new patient with a new diagnosis. | You came in for a follow-up visit regarding your pancreatic cancer treatment. |
| P2 | Slightly imprecise wording; it should specify the exact areas where the decrease was observed. | On CT scans, there was a significant decrease in the size of tumors in the pancr |

*Letter summary*: The letter contains inaccuracies and slight imprecision in wording.

---

## ROW 31 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | Missing cancer-related medication (gemcitabine). | We initially saw him two months ago. Because of his comorbidities and poor performance status, we re |
| P2 | Treatment_Changes | Supportive medication listed incorrectly as a change. | prochlorperazine (COMPAZINE) 5 mg tablet Take 1 tablet (5 mg total) by mouth every 6 (six) hours as  |

*Extraction summary*: Major error in missing gemcitabine under current medications. Minor issue with listing prochlorperazine as a change.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | This sentence contains medical jargon that may be difficult for an 8th-grade reader to understand. | Your white blood cell count is high, and your red blood cell count, hemoglobin,  |
| P2 | The term 'prochlorperazine' is not explained and might be confusing. | Prochlorperazine is being used as needed for nausea. |

*Letter summary*: The letter contains some medical jargon that may be challenging for an 8th-grade reader to understand.

---

## ROW 32 — ⚠️ ISSUES

**Type**: Metastatic moderately differentiated adenocarcinoma of pancreatic or biliary ori
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine) mentioned in the note. | There are several possible chemotherapy options for metastatic pancreatic cancer, with the choice of |
| P2 | Treatment_Changes | Supportive medications listed are not exclusively cancer-treatment-related. | Supportive medications include primary prophylaxis with growth factor support ([REDACTED] or Neupoge |
| P2 | Treatment_Goals | Goals of treatment are stated as 'palliative', but the note suggests a more nuanced approach including disease control and extending survival. | The mainstay of treatment at this point should consist of systemic therapy, that the goals of such t |
| P2 | Radiotherapy_plan | Plan is vague and lacks specific details. | For now, I will see how this responds to systemic therapy, but we could consider spot RT to that are |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing cancer-related medications, classification of supportive medications, and specificity of radiotherapy plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information (name of the medication). | You are inclined to move ahead with standard of care (SOC) chemotherapy. A new p |
| P2 | Unexplained jargon (grade _ neutropenia). | Supportive medications include primary prophylaxis with growth factor support (a |

*Letter summary*: Letter contains incomplete sentences and unexplained medical jargon.

---

## ROW 33 — ⚠️ ISSUES

**Type**: Metastatic pancreatic adenocarcinoma with biopsy-proven liver metastasis
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Lab_Results | The lab results include values not mentioned in the note. | The note does not provide specific lab values such as Alkaline Phosphatase, Bilirubin, Alanine trans |
| P2 | Current_Medications | The field is empty, but the note mentions several cancer-related medications. | The note mentions '*****' (likely a chemotherapy regimen) and 'irinotecan'. |
| P2 | Treatment_Changes | The field incorrectly states 'Switch to gemcitabine combined with nab-paclitaxel', which is part of the future plan, not a past change. | The note states 'my recommendation is to switch her therapy to gemcitabine combined with *****-pacli |
| P2 | Therapy_plan | The field incorrectly states 'Continue irinotecan', which is not part of the future plan. | The note recommends switching to gemcitabine combined with nab-paclitaxel. |

*Extraction summary*: Most fields are clean, but there are minor issues with lab results, current medications, treatment changes, and therapy plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate description of the cancer status. The note indicates 'interval increase in size of primary infiltrative necrotic pancreatic head mass' and 'similar in size and appearance of multiple hepatic metastases'. The letter incorrectly states that the cancer in the liver remains stable, which is misleading. | The CT scan of your abdomen and pelvis shows that the cancer in your pancreas ha |
| P2 | Unexplained jargon 'tumor markers'. | Your blood tests show high levels of tumor markers, indicating the cancer is sti |
| P2 | Missing information about the dosing schedule (days 1, 8, 15). | You will receive gemcitabine and nab-paclitaxel every 28 days. |

*Letter summary*: The letter contains inaccuracies and minor readability issues that need addressing.

---

## ROW 35 — ⚠️ ISSUES

**Type**: Adenocarcinoma of pancreatic tail
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions that the patient is on several medications, though none are cancer-related. | Current Outpatient Prescriptions: ERGOCALCIFEROL, VITAMIN D2, escitalopram oxalate, lisinopril, lora |
| P2 | Treatment_Changes | The field is empty, but the note discusses potential future treatment changes based on the results of the biopsy and lab tests. | My recommendation would be consideration of the ***** trial to determine if the patient has high ser |

*Extraction summary*: Most fields are clean, but there are minor issues with missing non-cancer medications and potential future treatment changes.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Use of 'hepatic lesions' is jargon that should be simplified to 'liver'. | You have pancreatic adenocarcinoma (cancer that started in gland cells) with fou |
| P1 | Incomplete sentence, missing the specific types of medications. | You will receive antiemetics and anti-diarrheal medications before starting chem |
| P1 | Unexplained jargon 'hereditary pancreatic cancer syndrome'. | We will request assistance from our genetic counselors for evaluation of a possi |

*Letter summary*: The letter contains minor readability issues and unexplained medical jargon that need addressing.

---

## ROW 36 — ⚠️ ISSUES

**Type**: Nonfunctioning pancreatic neuroendocrine tumor
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Everolimus is listed, but the note mentions multiple doses (2.5 mg and 10 mg). | everolimus (AFINITOR) 2.5 mg TAB 7.5 mg (3 tabs) daily  90 tablet  6    everolimus 10 mg TAB Take 1 |
| P2 | Treatment_Changes | Incomplete. The note mentions holding everolimus during partial SBO, but this detail is not fully captured. | Everolimus held during that period of time, resumed two weeks ago. |
| P2 | Treatment_Goals | Slightly imprecise. 'Palliative' is correct, but 'durable disease control' is also mentioned in the note. | with evidence of good durable disease control and reasonably good (in fact, improved) tolerance on c |
| P2 | Medication_Plan | Slightly imprecise. The note mentions starting non-insulin pharmacologic treatment in the future, but this is not clearly stated. | discussed potential plan to start non-insulin pharmacologic rx in the future. |

*Extraction summary*: Most fields are clean, but there are minor issues related to completeness and precision in medication details and treatment goals.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate description of the imaging findings. The original note states that some lesions have increased in size while others have decreased, but it does not specify 'shrunk'. | Some liver tumors have grown slightly, while others have shrunk. |
| P2 | The term 'neuroendocrine tumor' may still be confusing for an 8th-grade reading level. Simplifying further might be beneficial. | You came in for a follow-up visit regarding your neuroendocrine tumor of the pan |

*Letter summary*: The letter contains minor inaccuracies and readability issues that need addressing.

---

## ROW 40 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications (gemcitabine and Abraxane) in the medication plan. | We recommend a course of treatment with gemcitabine and Abraxane. |

*Extraction summary*: One minor issue identified regarding the inclusion of cancer-related medications in the medication plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information (dose amount). | We plan to increase the dose of your fentanyl and added Reglan and when necessar |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 41 — ⚠️ ISSUES

**Type**: Invasive adenocarcinoma of pancreatic head, well- to moderately differentiated, 
**Stage**: pT3N1 (Isolated tumor cells present in one lymph node out of 36 examined), now w

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication information. | He is continuing with an insulin regimen and regular use of enzyme supplements with meals. |
| P2 | Treatment_Changes | Missing supportive medication information. | He is continuing with an insulin regimen and regular use of enzyme supplements with meals. |
| P2 | Imaging_Plan | Note suggests further evaluation with PET/CT may be helpful for confirmation, but imaging plan states 'No imaging planned.' | Further evaluation with PET/CT may be helpful for confirmation. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medication information, supportive medication information, and an inconsistent imaging plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Use of 'ill-defined soft tissue' and 'superior mesenteric artery (SMA)' may be too technical for an 8th-grade reading level. | There is an increase in ill-defined soft tissue measuring up to 2.1 x 1.7 cm sur |

*Letter summary*: Letter is mostly clean but contains some technical terms that could be simplified for better readability.

---

## ROW 43 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Borderline resectable pancreatic adenocarcinoma due to <180 degrees of vascular 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | The note mentions 'Continue to monitor [REDACTED] July 04 [REDACTED] 4 weeks.' and 'Continue [REDACT |

*Extraction summary*: Most fields are clean, but the current medications related to cancer treatment are missing.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. | Your dose of Oxaliplatin and Irinotecan was reduced by 25%. Bolus 5FU was stoppe |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 59 — ⚠️ ISSUES

**Type**: Well to moderately differentiated adenocarcinoma of pancreatic origin with pulmo
**Stage**: Not explicitly mentioned in note, but with pulmonary recurrence documented in De

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note does not explicitly mention the stage of cancer, but inferring it as Stage IV due to pulmonary recurrence is reasonable. | With pulmonary recurrence documented in December 2017, likely progressed to Stage IV |
| P2 | Current_Medications.current_meds | The field is empty, but the note mentions several medications. However, none are specifically cancer-related. | None of the listed medications are cancer-specific treatments. |
| P2 | Treatment_Changes.recent_changes | The field is empty, but the note does not mention any recent changes in treatment. | No recent changes in treatment are mentioned. |
| P2 | Treatment_Changes.supportive_meds | The field is empty, but the note does not mention any recent changes in supportive medications. | No recent changes in supportive medications are mentioned. |
| P2 | Imaging_Plan.imaging_plan | The field only mentions 'CT Chest', but the note indicates ongoing surveillance which may include other imaging modalities. | She will continue on surveillance. |

*Extraction summary*: Most fields are clean, but there are minor issues with the inferred stage, empty medication fields, and incomplete imaging plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 62 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma
**Stage**: Originally Stage IIB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note does not explicitly state the original stage of the cancer as 'Stage IIB'. It only mentions metastatic disease. | The note states 'resected pancreaticobiliary cancer and rising markers..' and 'recurred with metasta |
| P2 | Treatment_Changes.recent_changes | The note mentions starting a treatment on 11/05/20, but the exact medication is redacted. The extraction should reflect this uncertainty. | Started [REDACTED] [REDACTED] 11/05/20 |
| P2 | follow_up_next_visit.Next clinic visit | The note does not specify the next clinic visit date, but it implies future visits are planned. | The note does not mention a specific next visit date. |

*Extraction summary*: Most fields are clean, but there are minor issues with the inferred original stage, the redacted treatment start, and the unspecified next visit date.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 72 — ⚠️ ISSUES

**Type**: Moderately differentiated adenocarcinoma
**Stage**: Originally borderline resectable, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | Missing current cancer-related medication (gemcitabine and Abraxane). | We elected to start gemcitabine and Abraxane. He has now had almost 4 cycles. |
| P2 | Treatment_Changes | Inconsistent mention of 'chemotherapy holiday'. The note mentions resuming chemotherapy after a holiday, but the extracted data only states starting gemcitabine and Abraxane without mentioning the holiday. | After 8 cycles, he had stable disease in the abdomen but progressing pulmonary metastases and we dec |

*Extraction summary*: Major error in missing current cancer-related medications and minor inconsistency in treatment changes.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 77 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the tail of the pancreas
**Stage**: Resectable at diagnosis, now on surveillance

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | The summary mentions 'follow-up visit for adjuvant therapy with gemcitabine and capecitabine', but the note states that he has already completed 6 cycles of adjuvant therapy. | He has had 6 cycles and is on surveillance. |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage is described as 'Resectable at diagnosis, now on surveillance'. While accurate, it could be more precise by specifying the current status as 'NED' (no evidence of disease). | Within this limitation, no evidence of recurrent or metastatic disease in abdomen or pelvis. |
| P2 | Treatment_Changes.recent_changes | The field is empty, but the note indicates that the patient has completed adjuvant therapy and is now on surveillance. This should be reflected. | He has had 6 cycles and is on surveillance. |
| P2 | Response_Assessment.response_assessment | The field states 'Not yet on treatment — no response to assess.' However, the patient has completed adjuvant therapy and is now on surveillance. | He has had 6 cycles and is on surveillance. |
| P2 | Imaging_Plan.imaging_plan | The imaging plan only mentions 'CT Abdomen', but the note suggests a comprehensive surveillance plan which may include both abdomen and chest imaging. | CT Abdomen /Pelvis without Contrast... CT Chest without contrast |

*Extraction summary*: Most fields are clean, but there are minor issues regarding the completion of adjuvant therapy and the specificity of the imaging plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The sentence is incomplete and lacks clarity about the surgical procedure. | You have adenocarcinoma (cancer that started in gland cells) of the tail of the  |
| P2 | The sentence uses technical terms that may be confusing. | However, your liver function tests show elevated levels of AST (162 U/L) and ALT |

*Letter summary*: The letter contains some issues with clarity and readability that need addressing.

---

## ROW 79 — ⚠️ ISSUES

**Type**: Adenocarcinoma of pancreaticobiliary origin
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions no cancer-related medications. | Medications the patient states to be taking prior to today's encounter. |
| P2 | Treatment_Changes | The field is empty, but the note mentions no recent treatment changes. | No explicit mention of recent treatment changes. |
| P2 | Lab_Plan | The field states 'No labs planned,' but the note suggests sending archived tumor specimen for molecular testing. | We discussed making sure his archived tumor specimen, if there is adequate cellularity, be sent for  |

*Extraction summary*: Most fields are clean, but there are minor issues with missing details related to lab plans and medication plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The term 'pancreaticobiliary' is not explained and may be confusing to an 8th-grade reader. | You were diagnosed with adenocarcinoma (cancer that started in gland cells) of p |
| P2 | The term 'hypermetabolic lesion' might be too technical for an 8th-grade reader. | Imaging and biopsy confirmed the presence of a complex cystic and solid mass in  |
| P2 | The sentence is incomplete and lacks context about the purpose of the MRI study. | Before starting treatment, you will undergo an MRI study. |

*Letter summary*: The letter contains minor readability issues and a slight lack of context that could be improved.

---

## ROW 82 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Stage IV (metastatic to liver and lung)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication (fentanyl patch). | fentaNYL (DURAGESIC) 25 mcg/hr patch Place 1 patch onto the skin every other day. For cancer pain. |

*Extraction summary*: One minor issue found in Current_Medications.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical info (missing 'FOLFOXIRI'). | We started a new treatment called modified a chemotherapy regimen, which include |

*Letter summary*: Letter contains an incomplete sentence with missing critical info.

---

## ROW 84 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma with perineural invasion
**Stage**: Originally Stage III, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Current medications should include both atezolizumab and cobimetinib. | Now midway through cycle #2 of treatment on the crossover arm of the same [REDACTED] trial consistin |
| P2 | Treatment_Changes | Incomplete. Should mention both atezolizumab and cobimetinib. | Switched to the combination of atezolizumab, a PD-L1 inhibitor (administered on a q2 weekly schedule |
| P2 | Treatment_Goals | Inaccurate. Should be 'palliative' rather than 'palliative'. | Thus far, he is tolerating treatment very well with no ***** or MEK-related toxicities, and maintena |
| P2 | Response_Assessment | Inaccurate. Should mention the slight increase in size of hepatic lesions. | Interval increase in size of hepatic segment 6 mass now measuring up to 7 cm with decreased associat |
| P2 | Medication_Plan | Incomplete. Should include both atezolizumab and cobimetinib. | Mr. [REDACTED] is continuing on the crossover arm of the [REDACTED] trial, consisting of atezolizuma |
| P2 | Therapy_plan | Incomplete. Should include both atezolizumab and cobimetinib. | Continue on the crossover arm of the [REDACTED] trial consisting of the combination of atezolizumab, |
| P2 | radiotherapy_plan | Incomplete. Should specify the type of radiotherapy. | At the point he progresses on this urgent regimen, we could have him see Rad Onc for consideration o |
| P2 | Procedure_Plan | Incomplete. Should specify the type of procedure. | At the point he progresses on this urgent regimen, we could have him see Rad Onc for consideration o |
| P2 | Genetic_Testing_Plan | Inaccurate. Should be 'pd-l1 expression' rather than 'pd-l1'. | pd-l1 |

*Extraction summary*: Most fields are clean, but there are several minor issues related to incomplete or slightly inaccurate information regarding current medications, treatment plans, and genetic testing.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | The term 'stable disease' might be confusing to an 8th-grade reader. | Your cancer is currently showing stable disease to treatment. This means that wh |
| P2 | The terms 'PD-L1 inhibitor' and 'MEK inhibitor' are technical and might confuse the reader. | You switched to a new treatment plan that includes atezolizumab (a PD-L1 inhibit |
| P2 | The term 'PD-L1 test' is technical and might confuse the reader. | We will also perform a PD-L1 test to guide future treatment decisions. |

*Letter summary*: The letter contains minor readability issues that could be improved for better clarity.

---

## ROW 87 — ⚠️ ISSUES

**Type**: Well-differentiated pancreatic neuroendocrine tumor (PNET) metastatic to the liv
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing octreotide, which is a cancer-related medication. | octreotide (SANDOSTATIN *****) 30 mg every 30 (thirty) days. |
| P2 | Treatment_Changes | Missing mention of increased metformin dosage. | Recent metformin and exercise for higher sugars- now fine. |
| P2 | Treatment_Goals | Should be 'palliative', but the note suggests ongoing management rather than end-of-life care. | Continue Everolimus 10 mg daily. |
| P2 | Response_Assessment | Inaccurate summary of response assessment. It should include the waxing and waning appearance of lung findings. | Left greater than right peripheral lower lobe reticulation and groundglass opacity is increased comp |
| P2 | Therapy_plan | Missing mention of monitoring triglycerides quarterly. | Continue to monitor Q 3 months. |
| P2 | Imaging_Plan | Missing specific timing for follow-up H&P and chest CT. | Needs f/u H&P and chest CT 3 mo-- sooner if sx. |
| P2 | Lab_Plan | Missing specific timing for follow-up MMA and B12. | On oral replacement- -needs f/u MMA, and B12 |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications, treatment changes, and specific timings for follow-ups.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 90 — ⚠️ ISSUES

**Type**: Primary pancreatic neuroendocrine tumor
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Cancer_Diagnosis.Type_of_Cancer | The note mentions both primary pancreatic neuroendocrine tumor and metastatic BRAF mutant melanoma, but the extracted data only lists 'Primary pancreatic neuroendocrine tumor'. | Regarding her metastatic ***** mutant melanoma (started on heel, 3 LNs in knee and 5 LNs in groin -> |
| P1 | Current_Medications.current_meds | The note indicates the patient is on intermittent dabrafenib and trametinib for melanoma, but this is not reflected in the extracted data. | continues on clinical trial, taking intermittent dabrafenib +***** ***** then trametinib alone ***** |
| P2 | Treatment_Changes.recent_changes | The note suggests reducing the dose of octreotide, but the extracted data does not clearly indicate the reason for the change. | Given documented ***** to liver-- favor trial of somatostatic analog (based on clarinet data showing |
| P2 | Treatment_Goals.goals_of_treatment | The note implies a mixed goal of managing both the pNET and melanoma, but the extracted data only states 'palliative'. | I'd like to avoid sunitinib or everolimus or chemotherapy given need for ongoing ***** inhibitor. |

*Extraction summary*: Major errors include missing metastatic BRAF mutant melanoma and current melanoma treatments. Minor issues involve unclear reasons for medication changes and incomplete treatment goals.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. | Your dose of octreotide was reduced for four days, then increased for another fo |

*Letter summary*: Letter contains an incomplete sentence that needs to be corrected.

---

## ROW 91 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas, moderately differentiated
**Stage**: Originally Stage III, now with residual adenocarcinoma and 8 of 23 lymph nodes p

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note does not specify the original stage of the cancer, only mentions 'early stage pancreatic adenocarcinoma'. The extracted 'Originally Stage III' is an assumption. | Mr. ***** is a 55 y/o man with a h/o HTN and a recent diagnosis of early stage pancreatic adenocarci |
| P2 | Treatment_Changes.recent_changes | The note mentions the patient has completed 6 cycles of therapy with gemcitabine and Abraxane, but the extracted data does not reflect any recent changes in treatment. | He has completed 6 cycles of therapy. His last 2 cycles were given with alternate week schedule usin |
| P2 | Treatment_Changes.supportive_meds | The note does not mention any specific supportive medications used during the treatment, but the absence of supportive medications might be worth noting. | None |
| P2 | Treatment_Goals.goals_of_treatment | The note suggests the patient has completed neoadjuvant therapy and surgery, and is now under surveillance. The goal 'curative' might be misleading without specifying the context of surveillance. | Currently, the patient is asymptomatic with stable disease. |
| P2 | Response_Assessment.response_assessment | The note mentions possible local recurrence, but the extracted response assessment does not reflect this possibility explicitly. | He may well have local recurrence but with the current coronavirus crisis, it will be difficult to w |

*Extraction summary*: Most fields are clean, but there are minor issues regarding the assumed original stage, lack of recent treatment changes, and the clarity of treatment goals and response assessment.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate description of the pathology results. It should mention 'residual adenocarcinoma' rather than just 'remaining cancer'. | The surgery showed some remaining cancer and 8 out of 23 lymph nodes were affect |
| P2 | Unexplained jargon 'thickening'. | Imaging shows some thickening in the area where the pancreas was, but you are cu |

*Letter summary*: There are minor issues with accuracy and readability that need addressing.

---

## ROW 92 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic ductal adenocarcinoma with perineural and l
**Stage**: Originally borderline resectable, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Type_of_Cancer | The note does not specify 'perineural and lymphovascular invasion' in the initial diagnosis. | Ms. ***** is a 63 y.o. female whom I am seeing at the UCSF Comprehensive Cancer Center for follow-up |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note mentions 'borderline resectable' initially, but the current stage is not explicitly stated as 'Stage IV'. | This pleasant woman was originally diagnosed with borderline resectable disease back in November 201 |
| P2 | Lab_Results.lab_summary | The note does not provide specific lab values for WBC, Hct, plts, Creat, AST/ALT, tot bili, alk phos, and CA 19-9. | Her *****-9 levels gradually ***** upwards, with a CT scan performed here at ***** on 12/10/2018 sho |
| P2 | Current_Medications.current_meds | The note does not mention any current cancer-related medications, but the patient is on chemotherapy. | She has since opted to resume chemotherapy with gemcitabine/*****-paclitaxel, well-tolerated to date |
| P2 | Treatment_Changes.recent_changes | The note does not mention any recent changes in treatment, but the patient has resumed chemotherapy. | She has since opted to resume chemotherapy with gemcitabine/*****-paclitaxel, well-tolerated to date |
| P2 | Response_Assessment.response_assessment | The note does not provide specific dates for the CT scan and CA 19-9 levels mentioned. | Postoperative scans have revealed no evidence of active disease in the liver and a slightly growing  |
| P2 | Imaging_Plan.imaging_plan | The note specifies 'repeat imaging in another 2-3 months', but the exact timing is not specified. | I would suggest continuing with the same regimen and following her with repeat imaging in another 2- |
| P2 | Lab_Plan.lab_plan | The note does not specify any lab plan other than monitoring CA 19-9. | I would suggest continuing with the same regimen and following her with repeat imaging in another 2- |

*Extraction summary*: Most fields are clean, but there are minor issues with the completeness and precision of certain details.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical info. | If your CA 19-9 levels rise significantly, further action will be considered. |

*Letter summary*: Letter contains an incomplete sentence that requires clarification.

---

## ROW 98 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine and Abraxane). | We initially saw her about 2 months ago. We recommended therapy with gemcitabine and Abraxane. |
| P2 | Treatment_Changes | Supportive medications listed are incomplete. Missing LORazepam (ATIVAN) and predniSONE (DELTASONE). | LORazepam (ATIVAN) 1 mg tablet... predniSONE (DELTASONE) 20 mg tablet... |
| P2 | Lab_Plan | Incorrect classification. Should be under 'Therapy_plan'. | Once we can get her albumin up to 2 or better, we can resume her chemotherapy. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications and misclassified lab plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

